Robert M. Califf

Adjunct Professor of Medicine
Donald F. Fortin, M.D. Distinguished Professor of Cardiology, in the School of Medicine
Member of the Duke Clinical Research Institute
Campus mail 100 Trent Drive, Suite401, Davison Building, Durham, NC 27710
Phone (919) 668-9222
Email address robert.califf@duke.edu

Robert Califf, MD MACC, is the Donald F. Fortin, MD, Professor of Cardiology. He is also Professor of Medicine in the Division of Cardiology and remains a practicing cardiologist. Dr. Califf was the Commissioner of Food and Drugs in 2016-2017 and  Deputy Commissioner for Medical Products and Tobacco from February 2015 until his appointment as Commissioner in February 2016. Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

Dr. Califf is a Member of the National Academy of Medicine (formerly known as the Institute of Medicine (IOM)) in 2016, one of the highest honors in the fields of health and medicine. Dr. Califf has served on numerous IOM committees, and he has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board's Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.

He has led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke's Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center and co-PI of the Patient Centered Outcomes Research Institute Network.

Publications

Tricoci, Pierluigi, Sergio Leonardi, Jennifer White, Harvey D. White, Paul W. Armstrong, Gilles Montalescot, Robert P. Giugliano, et al. “Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends.” J Am Coll Cardiol 62, no. 3 (July 16, 2013): 242–51. https://doi.org/10.1016/j.jacc.2013.04.043.

PMID
23684676
Full Text

Bethel, M Angelyn, Antonio R. Chacra, Prakash Deedwania, Gregory R. Fulcher, Rury R. Holman, Trond Jenssen, Steven E. Kahn, et al. “A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.” Am J Cardiol 112, no. 2 (July 15, 2013): 231–37. https://doi.org/10.1016/j.amjcard.2013.03.019.

PMID
23608615
Full Text

Diepen, Sean van, Anne S. Hellkamp, Manesh R. Patel, Richard C. Becker, Günter Breithardt, Werner Hacke, Jonathan L. Halperin, et al. “Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.” Circ Heart Fail 6, no. 4 (July 2013): 740–47. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000212.

PMID
23723250
Full Text

Mahaffey, Kenneth W., Anne S. Hellkamp, Manesh R. Patel, Karen L. Hannan, Kimberly Schwabe, Christopher C. Nessel, Scott D. Berkowitz, et al. “End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.” Circ Cardiovasc Qual Outcomes 6, no. 4 (July 2013): 470–78. https://doi.org/10.1161/CIRCOUTCOMES.113.000132.

PMID
23759472
Full Text

Eapen, Zubin J., Shelby D. Reed, Yanhong Li, Robb D. Kociol, Paul W. Armstrong, Randall C. Starling, John J. McMurray, et al. “Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF.” Circ Heart Fail 6, no. 4 (July 2013): 727–32. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000265.

PMID
23770519
Full Text

Mahaffey, Kenneth W., Daniel Wojdyla, Graeme J. Hankey, Harvey D. White, Christopher C. Nessel, Jonathan P. Piccini, Manesh R. Patel, et al. “Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.” Ann Intern Med 158, no. 12 (June 18, 2013): 861–68. https://doi.org/10.7326/0003-4819-158-12-201306180-00003.

PMID
23778903
Full Text

Anderson, Jeffrey L., Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, et al. “2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.” Circulation 127, no. 23 (June 11, 2013): e663–828. https://doi.org/10.1161/CIR.0b013e31828478ac.

PMID
23630129
Full Text

Anderson, Jeffrey L., Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, et al. “2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.” J Am Coll Cardiol 61, no. 23 (June 11, 2013): e179–347. https://doi.org/10.1016/j.jacc.2013.01.014.

PMID
23639841
Full Text

Hirsch, Bradford R., Robert M. Califf, Steven K. Cheng, Asba Tasneem, John Horton, Karen Chiswell, Kevin A. Schulman, David M. Dilts, and Amy P. Abernethy. “Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov.” Jama Intern Med 173, no. 11 (June 10, 2013): 972–79. https://doi.org/10.1001/jamainternmed.2013.627.

PMID
23699837
Full Text

Pages